These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16127031)

  • 1. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Vo G; Kabbara S; Kwa AL; Wiederhold NP; Lewis RE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3624-30. PubMed ID: 16127031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.
    Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
    Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
    Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
    J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
    Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa.
    Abraham N; Kwon DH
    FEMS Microbiol Lett; 2009 Sep; 298(2):249-54. PubMed ID: 19663916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.
    Bulman ZP; Sutton MD; Ly NS; Bulitta JB; Holden PN; Nation RL; Li J; Tsuji BT
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4343-6. PubMed ID: 25918151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.
    Smith NM; Bulman ZP; Sieron AO; Bulitta JB; Holden PN; Nation RL; Li J; Wright GD; Tsuji BT
    J Antimicrob Chemother; 2017 Aug; 72(8):2297-2303. PubMed ID: 28505268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
    Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
    Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.
    Landman D; Bratu S; Alam M; Quale J
    J Antimicrob Chemother; 2005 Jun; 55(6):954-7. PubMed ID: 15883174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.
    Tam VH; Kabbara S; Vo G; Schilling AN; Coyle EA
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2626-31. PubMed ID: 16870751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
    Lim TP; Lee W; Tan TY; Sasikala S; Teo J; Hsu LY; Tan TT; Syahidah N; Kwa AL
    PLoS One; 2011; 6(12):e28177. PubMed ID: 22162759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.
    Cai Y; Lim TP; Teo JQ; Sasikala S; Chan EC; Hong YJ; Lee W; Tan TY; Tan TT; Koh TH; Hsu LY; Kwa AL
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.
    Cai Y; Lim TP; Teo J; Sasikala S; Lee W; Hong Y; Chan EC; Tan TY; Tan TT; Koh TH; Hsu LY; Kwa AL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5238-46. PubMed ID: 27324776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.